Navigation Links
Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
Date:12/6/2010

interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts.  You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning.  Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission.  Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect.  Therefore, you should not rely on any such factors or forward-looking statements.  Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law.  The Private Securities Litigation Reform Act of 1995 permits this discussion.Contacts:MediaFritz Bittenbender610-883-5855fbittenb@cephalon.comInvestorsRobert (Chip) Merritt 610-738-6376cmerritt@cephalon.com
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 Sales Horizons, ... of its online sales training course – Mastering ... their sales performance. , Drawn from proven sales training ... companies, Mastering the Complex Sale online sales training course ... anyone who has face-to-face contact with customers, like technical ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
(Date:7/30/2014)... -- The Chicago Bears are excited to announce the team,s ... an effort to raise awareness of skin cancer. Through ... me™ skin cancer screenings at a preseason fan event ... SPOT me™ is an educational campaign designed to inform the ... skin cancer, and encourages people to get screened by ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... 6 Biocept, Inc. ("Biocept"), an,emerging leader in biotechnology, ... CEO, President and Director and the appointment,of Edward A. ... its former CEO, President and Director, Gordon F. Janko., ... highly regarded professional,in our field, and believe he is ...
... many genes encoding proteins that are similar to those of ... only a small fraction the genome, and there are many ... are these sequences doing, and do we really need them ... Genome Research ( www.genome.org ), researchers have delved ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ), today announced ... Department informed the Company that the,market value of ... 10,consecutive days, which is the requirement for continued ... Rule 4310(c)(3)(B). Nasdaq,also informed the Company that it ...
Cached Biology Technology:Biocept, Inc. Announces CEO and Director Appointments 2Use it or lose it? Researchers investigate the dispensability of our DNA 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3
(Date:7/30/2014)... is paving the way for a breakthrough that ... troops exposed to poisonous chemicalsparticularly those in pesticides ... the current issue of the journal ChemBioChem ... are compounds commonly used in pesticides and warfare ... School of Engineering Associate Professor of Chemical and ...
(Date:7/30/2014)... the potential effects of climate change on the ... the wrong factors, according to a new paper ... Society, University of Queensland, and other organizations. The ... is missing the point when it comes to ... climate change scientists focus on the "direct" threats ...
(Date:7/30/2014)... (OUP) is pleased to announce its new relationship with ... OUP and CINP will partner to publish International ... fully open-access journal. , Alan Frazer, Editor-in-Chief of ... and expertise of OUP will further facilitate the goal ... the very leading journals within neuropsychopharmacology. The conversion of ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2
... Oak Ridge National Laboratory researchers will lead projects that ... hours of computing time on supercomputers located at Oak ... were made through the U.S. Department of Energy (DOE),s ... (INCITE) program. This year, the INCITE program will make ...
... National Academy of Sciences ( PNAS ) Editorial Board ... 2009 Cozzarelli Prize, an award that recognizes outstanding contributions to ... Papers selected for the Cozzarelli Prize were chosen from ... in 2009 and represent the six broadly defined classes under ...
... than four months since launch, the first calibrated images ... of ,brightness temperature, translate into clear information on global ... our understanding of the water cycle. Launched on ... mission is improving our understanding of Earth,s water cycle ...
Cached Biology News:2010 DOE INCITE projects allocated at ORNL 22010 DOE INCITE projects allocated at ORNL 32010 DOE INCITE projects allocated at ORNL 4PNAS announces 6 2009 Cozzarelli Prize recipients 2First images from ESA's water mission 2First images from ESA's water mission 3
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: